太龙药业：根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险

证券之星04-17

证券之星消息，太龙药业(600222)04月17日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘，按新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险。谢谢您对公司的关注！投资者：请问董秘，按分红新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428908043?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-17 18:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2428908043","market":"sh","top_or_hot":-1,"title":"太龙药业：根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险","media":"证券之星","content":"<div>\n<p>证券之星消息，太龙药业(600222)04月17日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘，按新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险。谢谢您对公司的关注！投资者：请问董秘，按分红新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171805268b2e5ed2&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>太龙药业：根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n太龙药业：根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 18:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171805268b2e5ed2&s=b><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，太龙药业(600222)04月17日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘，按新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险。谢谢您对公司的关注！投资者：请问董秘，按分红新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171805268b2e5ed2&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171805268b2e5ed2&s=b","article_id":"2428908043","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404171805268b2e5ed2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2428908043","pubTimestamp":1713348272,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"证券之星消息，太龙药业04月17日在投资者关系平台上答复投资者关心的问题。谢谢您对公司的关注！本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600222":"太龙药业","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"Tailong Pharmaceutical: According to the latest relevant guidance and regulatory rules released by the China Securities Regulatory Commission and the stock exchange, there is currently no risk of the company being ST","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600222":0.9},"content_text":"证券之星消息，太龙药业(600222)04月17日在投资者关系平台上答复投资者关心的问题。投资者：请问董秘，按新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险。谢谢您对公司的关注！投资者：请问董秘，按分红新规，贵公司有无被实施ST的风险？太龙药业董秘：尊敬的投资者您好，根据证监会和交易所最新发布的相关指导意见和监管规则征求意见稿，目前公司不存在被ST的风险。谢谢您对公司的关注！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428908043"}